The GLP is committed to full transparency. Download and review our just-released 2019 Annual Report.

5 things to consider with direct-to-consumer health products

, | | April 11, 2019

Direct-to-consumer (DTC) versions of teeth alignment kits, genetic tests, hearing aids, heart-rhythm monitors, neurostimulation devices, and mental health tools are already on the market, causing professional organizations of dentistsgeneticistsaudiologistscardiologistsneurologists, and psychiatrists to grapple with challenges to their authority and practice.

Since 1976, the Food and Drug Administration has acted as a gatekeeper for companies bringing medical devices to the market. Today, however, many companies bypass the FDA by marketing quasi-medical products directly to consumers for “wellness” or “lifestyle” purposes.

First, alternative regulatory solutions that are better matched to the current direct-to-consumer health landscape are needed.

Related article:  Worried about genetic privacy? This start-up is offering anonymous DNA sequencing

Third, public information campaigns need to be waged with digital, not analog, tools. Watered-down statements from government agencies and patient pamphlets have little impact in today’s world.

Fifth, health professionals must become more informed about the direct-to-consumer health products in their respective fields. Rather than merely dismissing such products as invalid or irrelevant — which may discourage patients from talking about them — health professionals must recognize that their patients will have heard about these products and that they may present affordable, attractive options.

Read full, original post: 5 ways to address the challenges of direct-to-consumer health products

The GLP aggregated and excerpted this article to reflect the diversity of news, opinion, and analysis. Click the link above to read the full, original article.
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.

Send this to a friend